The MAPS Europe team is delighted to announce that screening of participants for our open-label Phase 2 study of MDMA-assisted therapy for PTSD has begun at the Charité – Universitätsmedizin Berlin and at South London and Maudsley NHS Foundation Trust as part of King’s College London (KCL-SLaM) in London, England, led by Principal Investigators Dr. Dimitris Repantis and Dr. James Rucker respectively
Similar research has already begun in the Netherlands, Norway, and the Czech Republic; plans are underway to expand to Spain and Portugal. The Phase 2 studies are in preparation for the initiation of Phase 3 research to gather data on safety and efficacy in support of applications to the European Medicines Agency (EMA) and England’s Medicines and Healthcare Products Regulatory Agency (MHRA) seeking approval for prescription use. These open-label Phase 2 studies of MDMA-assisted therapy for PTSD will include supervision as the providers work with the initial participants, a crucial element of therapist training.
